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A B S T R A C T
Background
Non-invasive positive pressure ventilation (NIPPV) is effective in treating acute exacerbations of chronic obstructive pulmonary disease
(COPD). Nocturnal non-invasive positive pressure ventilation (nocturnal-NIPPV) has been proposed as an intervention for stable
hypercapnic patients with COPD.
Objectives
To assess the effects of nocturnal-NIPPV at home via nasal mask or face mask in people with COPD by using a meta-analysis based
on individual patient data (IPD).
Search methods
We searched the Cochrane Airways Group Specialised Register. We performed the latest search in August 2012.
Selection criteria
Randomised controlled trials in people with stable COPD that compared nocturnal-NIPPV at home for at least five hours per night,
for at least three consecutive weeks plus standard therapy with standard therapy alone.
Data collection and analysis
IPD were collected and two review authors assessed risk of bias independently.
Main results
This update of the systematic review on nocturnal-NIPPV in COPD (Wijkstra 2002), has led to the inclusion of three new studies,
leading to seven included studies on 245 people. We obtained IPD for all participants in all included studies. The 95% confidence
interval (CI) of all outcomes included zero. These included partial pressure of CO2 and O2 in arterial blood, six-minute walking
distance (6MWD), health-related quality of life (HRQoL), forced expiratory volume in one second (FEV1), forced vital capacity
(FVC), maximal inspiratory pressure (PImax) and sleep efficiency. The mean effect on 6MWD was small at 27.7 m and not statistically
significant. Given the width of the 95% CI (-28.1 to 66.3 m), the real effect of NIPPV on 6MWD is uncertain and we cannot exclude
an effect that is clinically significant (considering that the minimal clinically difference on 6MWD is around 26 m).
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Authors’ conclusions
Nocturnal-NIPPV at home for at least threemonths in hypercapnic patients with stable COPDhad no consistent clinically or statistically
significant effect on gas exchange, exercise tolerance, HRQoL, lung function, respiratory muscle strength or sleep efficiency. Meta-
analysis of the two new long-term studies did not show significant improvements in blood gases, HRQoL or lung function after 12
months of NIPPV. However, the small sample sizes of these studies preclude a definite conclusion regarding the effects of NIPPV in
COPD.
P L A I N L A N G U A G E S U M M A R Y
Non-invasive positive pressure ventilation (ventilators) used at night by people with stable chronic obstructive pulmonary
disease (COPD)
Background: Non-invasive positive pressure ventilation (NIPPV) is a method to assist or replace spontaneous breathing (or normal
breathing) with the aid of a machine called a ventilator. A mask is fitted over the nose or mouth, or both and air is pushed into the
lungs. It can be used as a short-termmeasure, during critical instances in the hospital, but also at home for longer periods in people who
have raised levels of carbon dioxide in their blood. We wanted to discover whether using NIPPV at home during the night alongside
standard therapy was better or worse than standard therapy alone in people with chronic obstructive pulmonary disease (COPD).
COPD is a progressive disease that makes it hard to breathe. In 2002, we published our original Cochrane review looking at this. It
is important to check if new studies have been published that could be added to the existing studies in the review. In this review, we
performed a new search and found new studies and, therefore, this is an update of the review published in 2002.
What is individual patient data? In this review we used individual patient data. This means we collected original research data for
each participant from the original researchers who performed the studies. We used this information to perform our calculations.
Review question: What is the effect of NIPPV in people with COPD on blood gases, six-minute walking distance, health-related
quality of life, lung function, respiratory muscle function and sleep efficiency.
Study characteristics: The evidence is current to August 2012. We found seven studies that reported the effects of NIPPV at home.
Five of these studies looked at the effects after using NIPPV compared to regular treatment (without NIPPV) for at least three months.
Two studies looked for a longer period of time, for at least 12 months. The mean age of all participants included in our meta-analysis
was 67 years. All studies included men and women, but 77% of participants were men. We used data from 245 people for our meta-
analysis.
Results:NIPPV during the night for 3 and 12 months in people with COPD who had raised levels of carbon dioxide had no clinically
or statistically significant effect on gas exchange, six-minute walking distance, health-related quality of life, lung function, respiratory
muscle strength and sleep efficiency. This means we found little or no difference in the outcomes.
Quality of the results:Because some trials had very small numbers of participants, our confidence in the quality of evidence is moderate
when looking at the effects on gas exchange. All seven trials measured this outcome. Other outcomes were not always measured or
available leading to a lower quality of evidence for the other outcomes such as six-minute walking distance, health-related quality of
life, lung function, respiratory muscle function and sleep efficiency.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Nocturnal non- invasive positive pressure ventilation compared with standard treatment for severe COPD
Patient or population: adults with severe COPD
Settings: home treatment
Intervention: nocturnal non-invasive posit ive pressure vent ilat ion (nocturnal-NIPPV)1
Comparison: standard treatment




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Standard treatment Nocturnal-NIPPV




The mean PaO2 in the
control group was 53.2
mmHg
The mean PaO2 in the
intervent ion group was
1.30 higher









The mean PaCO2 in the
control group was 52.9
mmHg
The mean PaCO2 in the
intervent ion group was
2.50 lower








The mean 6MWD in the
control group was 324
m
The mean 6WMD in the
intervent ion group was
27.7 higher





Quality of life: SGQR
after 12 months
total score on a scale
f rom 0 to 100
The mean SGRQ in the
control group was 60.1
5
The mean SGRQ Total
score in the interven-
t ion group was 0.90
higher






Quality of lif e was
not measured af ter
3 months in any
study. Dif ferent ques-























































































































l if e af ter 12 months and
only the SGRQwas mea-






The mean FEV1 in the
control group was 0.82
L
Themean FEV1 in the in-
tervent ion group was0.
01 lower





* The basis for the assumed risk was the mean control group risk across studies.
6MWD: 6-minute walking distance; CI: conf idence interval; FEV1: f orced expiratory volume in 1 second; NIPPV: non-invasive posit ive pressure vent ilat ion; PaCO2: arterial
carbon dioxide tension; PaO2: arterial oxygen tension; SGRQ: total score on the St. George’s respiratory quest ionnaire.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Nocturnal non-invasive vent ilat ion was delivered through nose masks in f ive studies and by either a nasal or full-f ace mask
in two studies.
2 There was no signif icant change in PaO2 or PaCO2 af ter 12 months.
3 The conf idence intervals cross zero, therefore there was no dif ference and could include both possible benef it and harm.
4 The number of part icipants was low.
5 Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status.
6 The number of trials was low.






















































































































B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is an important
cause of morbidity and mortality worldwide. There are several
therapeutic options to help people with COPD manage their
symptoms, but to date, only smoking cessation and the provi-
sion of long-term oxygen therapy to hypoxic patients have been
shown to prolong life (Crockett 2001). Usually, treatment is with
bronchodilators and anti-inflammatory drugs (corticosteroids), al-
though the latter is still controversial in people withCOPD.When
medication doses are optimal and people still have dyspnoea or
an impaired exercise tolerance, pulmonary rehabilitation can be
added to medical therapy (Lacasse 2006). In people with more se-
vere COPD, bronchoscopic lung volume reduction (Slebos 2012),
lung volume reduction surgery (Cooper 1997), and, in extreme
cases, lung transplantation (Orens 2006), can be considered. In
people with COPD with chronic hypercapnic respiratory failure
nocturnal non-invasive positive pressure ventilation (nocturnal-
NIPPV) might be beneficial.
Description of the intervention
In non-invasive positive pressure ventilation (NIPPV), the person
receives ventilatory support through a non-invasive interface, such
as a nasal mask, full-facemask or helmet. NIPPV is currently ap-
plied as evidence-based therapy in people with COPD admitted
to hospital with acute hypercapnic respiratory failure due to an ex-
acerbation. It has been shown that NIPPV reduces hospital deaths
and complications associated with treatment and length of hospi-
tal stay (Ram 2004). NIPPV during an acute exacerbation is often
applied intermittently or continuously for a few days to reduce
the (life-threatening) ventilatory failure, after which the person is
weaned from ventilation and treatment is ended. Chronic noctur-
nal-NIPPV, however, entails the use of NIPPV at home during
the night for a longer period. Currently there is much discussion
about the need for NIPPV in COPD, mainly because conflicting
results have been published (Rossi 2000). There is consensus, but
with little supportive evidence, that people with COPDwho have
substantial daytime hypercapnia and superimposed nocturnal hy-
poventilation are most likely to benefit from NIPPV (Hill 2004).
How the intervention might work
Several theories exist as to why nocturnal-NIPPV might be benefi-
cial. First, nocturnal-NIPPV might rest chronically fatigued mus-
cles. Periods of rest may lead to recovery of the inspiratory mus-
cle function, thereby leading to an increased muscle strength and
endurance capacity of the respiratory muscles during the daytime
(Ambrosino 1990). Second, nocturnal-NIPPV has been shown to
improve sleep time and efficiency (Meecham 1995), as people with
severe COPD can experience poor sleep quality due to sleep-disor-
dered breathing with episodes of hypoventilation associated with
desaturation. Third, nocturnal-NIPPV may ameliorate nocturnal
hypoventilation and allow the respiratory centre to be reset. In this
way nocturnal-NIPPV may reduce daytime hypercapnia (Elliott
1991). Fourth, it is postulated that nocturnal-NIPPV decreases
hyperinflation leading to an improvement in respiratory mechan-
ics, such as an increase in forced expiratory volume in one second
(FEV1) and a decrease in residual volume (Duiverman 2011).
Why it is important to do this review
Despite all these theories, the effect of nocturnal-NIPPV in people
with stable severe COPD remains unclear and needs further inves-
tigation. This is an update of a Cochrane review first published in
2002. Since then, more studies have been reported, making an up-
date necessary. As in 2002, we performed a systematic review and
meta-analysis based on individual patient data (IPD). With IPD,
we collected original research data for each participant from the
original researchers for data checking, validation and re-analysis.
This gives an advantage over the conventional meta-analysis based
on summary statistics from published papers as more or different
analyses are possible. IPD meta-analyses have greater power, en-
abling investigation of additional hypothesis related to individual
characteristics, for example within subgroups or treatment across
trials, or both.
O B J E C T I V E S
To assess the effects of nocturnal-NIPPV at home via nasal mask
or face mask in people with stable COPD by using a meta-analysis
based on IPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) in people with stable COPD
comparing nocturnal-NIPPV at home plus standard therapy with
standard therapy alone.
Types of participants
People with COPD according to the guidelines of American Tho-
racic Society (ATS 1995).
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Types of interventions
NIPPV, applied through a nasal or face mask, for at least five hours
during the night, for at least three consecutive weeks. Participants
also received their usual standard COPD therapy, which com-
prised supplemental oxygen, bronchodilators, theophylline and
corticosteroids.
The intervention in the control group was standard therapy alone.
The control group did not receive nocturnal-NIPPV.
Types of outcome measures
Primary outcomes
1. Arterial blood gas tensions (partial pressure of carbon
dioxide in the blood (PaCO2), partial pressure of oxygen in the
blood (PaO2)).
2. Six-minute walking distance (6MWD).
3. Health status (health-related quality of life (HRQoL)
measurements).
Secondary outcomes
1. Lung function (FEV1 and forced vital capacity (FVC)).
2. Respiratory muscle function (muscle strength, including
maximal inspiratory pressure (PImax)).
3. Sleep efficiency (time asleep as percentage of total time in
bed.
4. Dyspnoea.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Specialised
Register (CAGR), which is maintained by the Trials SearchCo-or-
dinator for theGroup.TheRegister contains trial reports identified
through systematic searches of bibliographic databases including
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and
handsearching of respiratory journals and meeting abstracts (see
Appendix 1 for further details).
For the original version of this review we carried out a search on all
COPD records in the Register using the terms: nasal ventilat* OR
positive pressure OR NIPPV. For this update, a search was done
in all COPD records in the Register using the following search
string:
(nasal OR mechanical OR noninvasive OR non-invasive or “non
invasive” or positive OR intermittent OR bi-level OR “bi level”
OR airway* OR controlled OR pressure OR support AND (ven-
tilat*)) OR (NIPPV).
We conducted this most recent search in August 2012.
Searching other resources
We searched the bibliographies of each RCT for additional papers
thatmay have contained RCTs.We contacted authors of identified
RCTs for other published and unpublished studies.
Data collection and analysis
Selection of studies
For the 2002 version of this review, two review authors (PJW,
RSG) independently assessed all identified abstracts and for the
2013 update this was done by PJW and FMS. When we selected
an abstract, full papers were retrieved and read in detail by the same
two review authors and disagreements were resolved by discussion
with a third review author.
Data extraction and management
After identification of studies, we contacted trial authors to ask for
the IPD including anthropometric data and follow-up data of the
identified outcome variables. We requested missing data from the
included primary studies from the authors. We checked supplied
data against study publications after which we copied raw data
from all included studies to one main database.
Assessment of risk of bias in included studies
Two review authors (FMS and PJW) assessed risk of bias of
each study independently (for details see ’Risk of bias’ table in
Characteristics of included studies). We used criteria for assess-
ment of risk of bias as provided in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We considered
potential for bias using the following domains:
• sequence generation;
• allocation concealment;
• blinding of participants, personnel and outcome measures;
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We judged each domain as ’high’, ’low’ or ’unclear’ risk of bias. If
insufficient details were reported, the judgement was ’unclear’ of
risk of bias.
Measures of treatment effect
The principal investigators of all the trials included in the meta-
analysis kindly provided the individual data for each of their study
subjects. We therefore conducted an individual data meta-analy-
sis. We expressed study outcomes in the same natural units across
the trials. For each individual and for each outcome, we calculated
an absolute difference in score that defined treatment effect. An
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overall treatment effect (mean difference and associated 95% con-
fidence interval (CI)) was obtained from the difference in scores
under each study condition (NIPPV minus controls). Different
proportions of participants contributed to the different outcomes.
Unit of analysis issues
In the case of cross-over trials, we considered only the first study
period (prior to the cross-over).
Dealing with missing data
We contacted trialist and obtained IPD for all trials.
Assessment of heterogeneity
To consider the homogeneity among trials, a random factor was
defined in the statistical models. Statistical significance (P value
< 0.05) in the test of homogeneity suggested that the observed
difference in the treatment effects was in part attributable to the
study effect.
Assessment of reporting biases
We planned to inspect a funnel plot visually if we were able to
meta-analyse 10 or more trials for an outcome.
Data synthesis
We analysed IPD using a linear mixed model to compare the
treatment effects. Treatment and time of follow-up (3 and 12
months) were analysed with interaction terms as fixed factors. We
performed all the analyses using SAS version 9.3 (SAS Institute,
Caru, NC).
Subgroup analysis and investigation of heterogeneity
We considered subgroup analyses if sufficient numbers of studies
and a large enough sample size were to be included in the analysis
and if we found significant heterogeneity among the outcomes of
the trials. We identified a priori potential sources of heterogeneity
among the primary and secondary outcomes. We postulated the
following sources of heterogeneity:
1. the more hypercapnic patients might benefit more from
NIPPV;
2. the benefits of NIPPV might be greater among those who
used it for longer periods;
3. people who received higher levels of inspiratory airway
pressure (IPAP) might have a greater benefit of NIPPV.
R E S U L T S
Description of studies
See: Characteristics of included studies.
Results of the search
The search conducted up to August 2012 identified 687 records
of which we retrieved 17 full-text papers for further examination.
We reduced the publications to 14 potentially eligible papers. We
excluded five studies for the following reasons: not randomised
(Clini 1998; Kamei 1999); duration of NIPPV too short (less than
four hours per night and at daytime) (Diaz 1999; Renston 1994);
training of NIPPV too short (less than three weeks) (Lin 1996).
One study is awaiting classification as the authors failed to re-
spond to clarify important issues (Xiang 2007). This update iden-
tified three new trials (Clini 2002; McEvoy 2009; Sin 2007), and
together with the four trials from the original review (Casanova
2000; Gay 1996; Meecham Jones 1995; Strumpf 1991), we in-
cluded seven studies in the meta-analysis.
Included studies
Seven studies met the inclusion criteria for the review (Casanova
2000; Clini 2002; Gay 1996; McEvoy 2009; Meecham Jones
1995; Sin 2007; Strumpf 1991). The Characteristics of included
studies table shows full details of the included studies. Five studies
provided data on NIPPV after three months and are classified as
’short term’ (Casanova 2000; Clini 2002; Gay 1996; Meecham
Jones 1995; Sin 2007), while two studies provide data after 12
months and are defined as ’long term’ (Clini 2002;McEvoy 2009).
We obtained IPD for each of these studies from the trial authors.
We provided summary details below.
Trial design
Five studies were parallel in design (Casanova 2000; Clini 2002;
Gay 1996; McEvoy 2009; Sin 2007) and two were cross-over in
design (Meecham Jones 1995; Strumpf 1991).
Participants
The seven included studies were based in different countries: Spain
(Casanova 2000), Italy (Clini 2002), USA (Gay 1996; Strumpf
1991), Australia (McEvoy 2009), UK (Meecham Jones 1995), and
Canada (Sin 2007). Five studies compared nocturnal-NIPPV with
standard treatment (Casanova 2000; Clini 2002; McEvoy 2009;
Meecham Jones 1995; Strumpf 1991), and two studies compared
nocturnal-NIPPV with sham treatment in the form of continuous
positive airway pressure (CPAP) at 2 and 4 cm H2O (Gay 1996;
Sin 2007). Nocturnal-NIPPV was delivered through a nasal mask
in five studies (Casanova 2000; Clini 2002; Gay 1996; Meecham
Jones 1995; Strumpf 1991), and by a either a nasal or full-face
mask in two studies (McEvoy 2009; Sin 2007). The mean age of
all participants included in the IPDmeta-analysis was 67 years. All
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studies included men and women; 77% were men. Mean FEV1
was 0.73 L and mean PaCO2 was 53 mmHg. Mean IPAP for the
short-term studies was 14.7 cmH2Oand for the long-term studies
was 13.6 cm H2O. Nocturnal-NIPPV was applied for a mean of
6.7 hours in the short-term studies and 6.6 hours in the long-term
studies.
Funding of trial
Six studies were funded by their National Respiratory Society/
Foundation (Casanova 2000; Clini 2002; Gay 1996; McEvoy
2009; Meecham Jones 1995; Sin 2007), from which two were
also partly funded by an industrial company (Clini 2002;McEvoy
2009). One study was funded by an industrial company alone
(Strumpf 1991).
Excluded studies
The Characteristics of excluded studies table provides full details
of the excluded studies.
Risk of bias in included studies
The Characteristics of included studies table provides details of
risk of bias in the included studies. Figure 1 shows a summary of
our risk of bias judgements across studies.
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Figure 1. Risk of bias summary: review authors’ judgements about each methodological quality item for
each included study.
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Allocation
All studieswere described as randomised anddescribed themethod
of randomisation adequately. Allocation concealment was also
deemed to be adequate in all studies, four of themdescribing a cen-
tralised randomisation office or independent person. In the other
three cases, sequentially numbered, opaque, sealed envelopes were
used.
Blinding
Given the nature of the intervention it can be difficult to blind
participants; however, two studies used a sham-device (Gay 1996;
Sin 2007). In one study, personnel were also blinded for the treat-
ment allocation making this the only study that we could clas-
sify as a low risk of bias in this area (Sin 2007). Three studies
had blinding for all physiological measurements (Casanova 2000;
Clini 2002; Strumpf 1991), two had no blinding (McEvoy 2009;
Meecham Jones 1995), and one was unclear (Gay 1996). How-
ever, we judged that outcome measurement was not likely to be
influenced by lack of blinding for personnel and, therefore, overall
we judged all studies as low risk of bias.
Incomplete outcome data
In one of the cross-over studies, only seven out of the 19 ran-
domised participants completed both arms (Strumpf 1991). An-
other study reported that four out of seven participants ran-
domised to NIPPV completed the trial, as opposed to all six in
the sham group (Gay 1996). Both studies were classified as high
risk of attrition bias. Two other studies also had dropouts and did
not perform intention-to-treat (ITT) analyses but as numbers due
to intolerance were small these studies were classified as low risk
(Meecham Jones 1995; Sin 2007). The three remaining studies all
reported ITT analyses as well as per-protocol-analyses (or stated
that “Inclusion of the patients who did not complete the trial (in-
tent to treat) did not affect any of the outcomes”) and were there-
fore considered as low risk of bias (Casanova 2000; Clini 2002;
McEvoy 2009). In addition, in the long-term studies, reasons for
missing data were not substantially different between both groups,
for example; not being able to come for re-testing due to a wors-
ening of the disease (Clini 2002; McEvoy 2009).
Selective reporting
Wecouldnot find the original protocols to check if the prespecified
outcomes were all reported in the articles, so in this area the risk
of bias was unclear. However, all outcomes listed in the methods
section of the studies were reported in the results section.
Other potential sources of bias
We did not find any other sources of bias.
Effects of interventions
See: Summary of findings for the main comparison Nocturnal
non-invasive positive pressure ventilation compared with standard
treatment for severe COPD
Table 1 shows the results of themeta-analysis based on IPD. There
is a difference between the number of participants included in the
studies and the number included in the meta-analysis. There were
some dropouts in most studies, for the short-term follow-up this
was often due to intolerance of the nose mask, intercurrent infec-
tions or participants no longer meeting the inclusion criteria after
a stabilisation period. In both studies looking at long-term effects,
this was often due to progression of the disease and reluctance
of participants to return to hospital for follow-up measurements.
Finally, not all parameters were measured in all participants and,
therefore, there is a difference in number of participants per out-
come. In total, 245 participants were included in the IPD meta-
analysis.
Arterial blood gas tensions
Three-month follow-up: all five short-term studies contributed
data towards this outcome (Casanova 2000; Gay 1996; Meecham
Jones 1995; Sin 2007; Strumpf 1991), as well as the Italian long-
term study (Clini 2002), which also provided data after three
months. In total, 162 participants were analysed for blood gases.
The 95% CI of PaO2 and PaCO2 included zero, hence they were
not statistically significant. PaCO2 did show a trend towards sig-
nificance with the 95% CI only just exceeding zero (mean differ-
ence (MD) -2.50, 95% CI -5.28 to 0.29).
Twelve-month follow-up: two studies (Clini 2002; McEvoy
2009), with 118participants gathered data for this outcome.There
was no significant difference in PaO2 and PaCO2 between stan-
dard care and NIPPV groups after 12 months (PaO2 MD -1.77,
95% CI -8.60 to 5.07; PaCO2 MD -0.96, 95% CI -3.55 to 1.64).
Six-minute walking distance
Three-month follow-up: three studies with 40 participants mea-
sured 6MWD(Gay 1996;Meecham Jones 1995; Sin 2007).Meta-
analysis showed a moderate treatment effect on 6MWD (MD
27.7, 95% CI -11.0 to 66.3), but this difference was not statisti-
cally different. Exercise endurance was reported by one study and
determined by measuring treadmill walking time and could not
be included in the meta-analysis (Strumpf 1991).
Twelve-month follow-up: as only one study measured 6MWD
after 12 months meta-analysis was not possible (Clini 2002).
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Health status
Three-month follow-up: only one study measured HRQoL after
three months using the St. George’s Respiratory Questionnaire
making meta-analysis impossible (Meecham Jones 1995).
Twelve-month follow-up: Both long-term studies measured
HRQoL in 103 participants after 12 months using three differ-
ent questionnaires (Short Form-36 item (SF-36) questionnaire by
McEvoy 2009; Maugeri Respiratory Failure questionnaire-28 by
Clini 2002; St. George’s Respiratory Questionnaire by Clini 2002
andMcEvoy 2009), making it possible to only combine results for
the St. George’s Respiratory Questionnaire. The overall treatment
effect was very small and was not significant (MD 0.90, 95% CI
-19.21 to 21.01) and was found to be heterogeneous (P value =
0.03).
Lung function
Three- month follow-up: all five short-term studies with 83 par-
ticipants provided data for FEV1 and FVC (Casanova 2000; Gay
1996;Meecham Jones 1995; Sin 2007; Strumpf 1991). Very small
and non-significant results were found for FEV1 (MD -0.01 L,
95% -0.09 to 0.07) and no effects were found for FVC (MD 0.00
L, 95% CI -0.13 to 0.14) after three months.
Twelve-month follow-up: both long-term studies measured
FEV1 and FVC in 125 participants after 12 months (Clini 2002;
McEvoy 2009). The 95% CIs of FEV1 and FVC included zero
(FEV1 MD-0.01 L, 95%CI -0.07 to 0.04; FVCMD0.04 L, 95%
CI -0.12 to 0.20), hence they were not statistically significant.
Respiratory muscle function
Three-month follow-up: three studies with 48 participants pro-
vided data for PImax and PEmax (Casanova 2000; Gay 1996;
Strumpf 1991). The improvement in PImax was not statistically
different (MD 4.87 cm H2O, 95% CI -1.48 to 11.21). PEmax
showed a non-significant improvement after threemonths NIPPV
(MD 22.09 cm H2O, 95% CI -23.53 to 67.70) but with sig-
nificant heterogeneity. The 95% CI was very wide, probably due
to the small number of trials and consequently participants, and
therefore we did not perform subgroup analyses.
Twelve-month follow-up: as only one study reported data on
PImax (Clini 2002), and none on PEmax, no meta-analyses were
undertaken for these outcomes.
Sleep efficiency
Three-month follow-up: three studies with 24 participants pro-
vided data for sleep efficiency (Gay 1996; Meecham Jones 1995;
Strumpf 1991) showing a small negative effect after three months
(MD -9.11, 95% CI -38.09 to 19.86). This effect was heteroge-
neous. The study by Strumpf et al with only seven participants,
reported a very broad 95%CI (MD25.4, 95%CI -69.17 to 70.4).
Subgroup analysis was not performed due to the low number of
trials.
Twelve-month follow-up: sleep quality was measured differently
by both long-term studies. One reported on sleep efficiency by
measuring time asleep as percentage of total time in bed (McEvoy
2009), but only performed follow-upmeasurements in theNIPPV
group. The other study also measured sleep quality but by means
of a semi-qualitative multipoint scale of 1 to 4 (Clini 2002). No
meta-analyses could be performed.
Dyspnoea
Three-month follow-up: dyspnoea was measured in two studies,
but as they were measured with different scales (the Medical Re-
search Council (MRC) scale and Borg scale by Casanova 2000 or
Transitional Dyspnea Index (TDI) by Strumpf 1991), data could
not be combined.
Twelve-month follow-up: one study (Clini 2002) measured dys-
pnoea after 12 months by means of a 6-point MRC score. No
meta-analysis could be performed.
D I S C U S S I O N
Summary of main results
In this update, IPD from three new studies were added to the
original review (Wijkstra 2002), and two of these studies were
conducted over 12 months, which means we now have some long-
term data on which to base our conclusions, including long-term
information on quality of life outcomes. Nocturnal-NIPPV at
home for at least three months in hypercapnic patients with stable
COPD had no consistent clinically or statistically significant ef-
fect on gas exchange, exercise tolerance, lung function, respiratory
muscle strength or sleep efficiency. Meta-analysis of the two new
long-term studies did not show significant improvements in blood
gases, HRQoL or lung function after 12 months of NIPPV.
Overall completeness and applicability of
evidence
In this meta-analysis, we did not find statistically significant effects
in any included outcomes. By adding data of PaCO2 after three
months from two studies in this update, the improvement of 2.5
mmHg was still not significantly different but the CIs now only
just exceeded zero. The small sample size precludes a definitive
statement regarding the clinical implications ofNIPPV, other than
stating that at present there is insufficient evidence to support its
widespread use.
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Although the improvement of 27.7 m in the 6MWD is not statis-
tically significant, it could be clinically significant as it does reach
the clinicallyminimal important difference of 26m (Puhan 2011).
This meta-analysis of 6WMD after three months, however, was
only based on 40 participants and although not contributing to
the meta-analysis, the long-term study of Clini 2002 looking at
effects on 6MWD after 12 months of NIPPV only found a very
small improvement of 3.2 m (95% CI -49.7 to 56.1) in 46 par-
ticipants.
The upper limit of the CI of 66 m for the 6MWD in the meta-
analysis suggests that it remains possible that NIPPV has beneficial
effects on walking in at least some people, but it is not possible to
identify these people a priori. Additional studies with larger sample
sizes that address participant selection, ventilator settings, training
and NIPPV compliance should clarify the role of this treatment.
Not all outcomes could be combined because of measurements
with different scales. Dyspnoea was measured in three studies, but
as this was measured with the 5-pointMRC scale (Casanova 2000)
and 6-point MRC scale (Clini 2002), Borg (Casanova 2000), or
TDI (Strumpf 1991) anddifferent lengths of follow-up, data could
not be combined. The same applied to HRQoL; three studies ex-
amined this outcome but all used different questionnaires ranging
from the more generic SF-36 questionnaire (McEvoy 2009) and
the (lung) disease specific St. George’s Respiratory Questionnaire
(Clini 2002;McEvoy 2009;Meecham Jones 1995) to theMaugeri
Respiratory Failure questionnaire-28 (MRF-28) (Clini 2002), de-
signed for people with respiratory failure. For future studies, it
would be of great benefit if the same questionnaires were to be
used making comparison and pooling of data possible. The effect
of NIPPV may not be captured by the HRQoL questionnaires
currently analysed. Several studies have shown good reliability and
validity of the Severe Respiratory Insufficiency (SRI) questionnaire
and the MRF-28, specifically for people with COPD with hyper-
capnic respiratory failure (Duiverman 2008; Windisch 2003). It
has been suggested to use both these questionnaires, as the SRI
focuses more on psychological aspects and theMRF-28 focuses on
restrictions of daily living. But moreover, a large trial also looking
at the effect of NIPPV on survival, exacerbation frequency and
admissions is needed.
Quality of the evidence
Seven (three new to this update) RCTs with individual data from
245 people were included in this systematic review. Meta-analysis
was performed when trials used similar outcome measures. Short-
term trials were analysed as one group,measuring effects ofNIPPV
after three months. Long-term trials comprised the second group,
measuring effects of NIPPV after 12 months. All studies described
how randomisation was performed and described adequate allo-
cation concealment. Mainly the short-term studies had few par-
ticipants (between 7 and 36 participants) and sometimes showed
large CIs for some outcome measures such as PImax (Strumpf
1991). Two studies show a high dropout rate after randomisa-
tion because people were not able to tolerate NIPPV (Gay 1996;
Strumpf 1991). Only results from the completers were reported,
which could make outcomes susceptible to selection bias. In the
other studies, dropout due to non-tolerance was considered small.
The two larger studies with long-term follow-up had quite large
dropout rates but mainly due to progression of the disease and
unwillingness to repeat tests; these were similar amounts between
groups. Both studies performed ITT analysis and per-protocol
analysis. In this systematic update we only included complete data.
The meta-analysis in this review was performed based on IPD.
Treatment effects can, therefore, be seen asmore conservative (with
wider CIs). They take into account not only interstudy variation,
but also intrastudy variation.
Potential biases in the review process
Limitations regarding the setup of the meta-analyses
The design of this meta-analysis included only studies in which
nocturnal-NIPPVwas applied for at least five hours per night. This
excluded two studies that reported beneficial effects from NIPPV
administered for two hours during the day (Diaz 1999; Renston
1994). In keeping with the application of mechanical ventilatory
support for people with thoracic restriction or neuromuscular con-
ditions, we considered night-time ventilation to be the most ap-
propriate clinical approach and reasoned that several hours would
be required to achieve therapeutic goals. Furthermore, aminimum
duration of three weeks was chosen, as from our own clinical ex-
perience we were aware that it might take up to two weeks just
for mask fitting, adjustment and patient familiarisation with non-
invasive ventilation. Therefore, one study in which NIPPV was
assessed for only two weeks was excluded from the analysis (Lin
1996).
Limitations regarding the included studies
We included RCTs that determined the effects of NIPPV versus
normal medical treatment. However, it is questionable whether
NIPPV with IPAP pressures below 14 cm H2O is enough to im-
prove ventilation. As the most appropriate NIPPV settings have
yet to be established, it is unclear whether pressures of 10 to 14 cm
H2Oare the optimal pressures for improving ventilation in people
with COPD (Casanova 2000; Gay 1996). Since the 1990s, sev-
eral non-randomised trials studied a new form of NIPPV aimed at
maximally reducing PaCO2 levels bymeans of high IPAPpressures
(Windisch 2009). This form is called high-intensity NIPPV (HI-
NIPPV) where pressures are carefully increased from 20 H2O up
to 40 H2O depending on patient comfort and tolerance. These
studies all had a mean IPAP of around 30 H2O and showed im-
provements in blood gases and alveolar ventilation during spon-
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taneous breathing, and also improvements in lung function and
HRQoL. One randomised controlled cross-over trial subsequently
followed comparing six weeks of HI-NIPPV (mean IPAP 29H2O
in controlled mode) to six weeks of low-intensity NIPPV (mean
IPAP 15 H2O in assist mode) (Dreher 2010). Thirteen people
completed the trial and a mean treatment effect on PaCO2 of
9.2 mmHg (95% CI -13.7 to -4.6) in favour of HI-NIPPV was
shown, as well as an improved FEV1, FVC andHRQoL as assessed
by the SRI. Somewhat surprisingly, participants showed a higher
compliance in the HI-NIPPV group. One randomised cross-over
study of 15 people was performed to investigate the acute phys-
iological changes during 30 minutes of both forms of NIPPV in
stable COPD (Lukácsovits 2012). Significant improvements in
PaCO2 during HI-NIPPV (mean IPAP 28 H2O) compared to
low NIPPV (mean IPAP 18 H2O) were also found in this study,
However, the decrease in cardiac output was significantly more
pronounced with HI-NIPPV, leading the authors to speculate on
possible limitations of this method for people with pre-existing
cardiac disease.
One published, long-term RCT that compared the effects of
NIPPV, not to standard care, but in addition to rehabilitation
(Duiverman 2011), showed a significant decrease in PaCO2 in the
NIPPVplus rehabilitation group as compared to the rehabilitation
only group. Interestingly, although mean levels of IPAP after three
months were 20 cm H2O and after two years were 23 cm H2O,
there was no relationship identified between the change in PaCO2
and the level of IPAP (or with the inspiratory pressure difference
(IPAP minus EPAP)). Change in PaCO2 after three months did
correlate with baseline PaCO2 or with the number of hours of
NIPPV use per day.
Agreements and disagreements with other
studies or reviews
In 2007, one systematic review on NIPPV in people with stable
COPD was published (Kolodziej 2007). An important difference
with this systematic review is the inclusion of non-RCTs. They
found improvements in blood gasses, hyperinflation and work of
breathing, but only in a combined analysis of non-randomised
trials with evident heterogeneity. This heterogeneity was probably
the result of including studies with different lengths of follow-up,
usages per day and types of ventilation (during the day or at night).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Nocturnal-non-invasive positive pressure ventilation at home for
3 and 12 months in hypercapnic patients with COPD had no
clinically or statistically significant effect on gas exchange, exercise
tolerance, quality of life, lung function, respiratorymuscle strength
or sleep efficiency.
Implications for research
Future research should focus on adequate patient selection, ven-
tilator settings, training and length of ventilation, as well as ex-
acerbation frequency, admissions to hospital and survival. During
ventilation, people should be monitored carefully, to observe more
precisely the changes that are occurring with non-invasive ventila-
tion. Long-term non-invasive ventilation for people with COPD
should only be started in the context of a clinical trial, preferably
with agreed upon common outcome parameters.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Casanova 2000
Methods Randomised, parallel, controlled study
Participants 52 people with COPD, FEV1 0.85 L, PaCO2 51 mmHg. Raw data for 36 people with
COPD, FEV1 0.84 L, PaCO2 51 mmHg
Interventions 26 people received standard care plus nocturnal-NIPPV (IPAP 12 to 14, EPAP 4) for
12 months, while the other 26 continued optimal standard care
Outcomes After 3 months: BGA, lung function, dyspnoea (MRC and Borg scale), PImax/PEmax
After 12 months: exacerbation rate, hospital admissions, intubations and mortality
Notes Funding: supported in part by a grant from the Spanish Respiratory Society
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The 52 patients who met the study
criteria were randomised by an independent
office into two groups using a table of random
numbers”
Allocation concealment (selection bias) Low risk Quote: “Randomised by an independent of-
fice using a table of random numbers”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants: no blinding for treatment
Quote (from correspondence): “Blinded: for
gas exchange and lung function”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Inclusion of the patients who did not
complete the trial (intent to treat) did not af-
fect any of the outcomes”
Selective reporting (reporting bias) Unclear risk All outcomes listed in the Methods were re-
ported
Other bias Low risk The study appears to be free of other source of
bias
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Clini 2002
Methods Randomised, parallel, controlled study
Participants 90 people with COPD randomised; FEV1 %predicted 29, PaCO2 55 mmHg. Raw data
for 80 people with COPD, FEV1 0.75 L, PaCO2 56 mmHg
Interventions 43 people received standard care plus nocturnal-NIPPV (IPAP 14, EPAP 2) for 24
months and 47 continued optimal standard care
Outcomes After 3 months: BGA, hospitalisations
After 12 months: BGA, lung function, dyspnoea (MRC), 6MWD, PImax, sleep studies
(4-point scale), QoL (SGRQ and MRF-28) and hospitalisation
Notes Funding: this study was supported by AIPO (Italian Association of Hospital Pulmonolo-
gists) and Markos-Mefar through Air Liquide Group Italia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...a centralised randomisation was
used”
Allocation concealment (selection bias) Low risk Quote: “Because of the small number of eligi-
ble patients in each centre, a centralised ran-
domisation was used. Blocks were used to pro-
vide balanced groups in the overall enrolment
(not inside each centre)”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants: no blinding for treatment
Quote: “All physiological measurements were
performed by personnel blind to treatment
and not involved in the study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Main parameters were evaluated both
in terms of patient completers and of inten-
tion-to-treat”
Selective reporting (reporting bias) Unclear risk All outcomes listed in the Methods were re-
ported
Other bias Low risk The study appears to be free of other source of
bias
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Gay 1996
Methods Randomised, parallel, controlled study.
Participants 13 people with COPD randomised, FEV1 0.67 L, PaCO2 52 mmHg. Raw data for 10
people with COPD, FEV1 0.68 L, PaCO2 52 mmHg
Interventions 7 people received nocturnal-NIPPV (IPAP 10, EPAP 2) for 3 months, while 6 received
sham NIPPV (with maximal medical care)
Outcomes After 3 months: BGA, lung function, 6MWD, sleep study (sleep efficiency), PImax/
PEmax
Notes Funding: this study was supported in part by Grant MOl RR 00585 from the National
Institutes of Health, Public Health Service, and the Mayo Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “By randomisation...”
Allocation concealment (selection bias) Low risk Quote (from correspondence): “It was done
with a sealed envelope randomisation tech-
nique”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants: blinded for intervention (as it
was NIPPV versus sham)
Personnel: unknown
Incomplete outcome data (attrition bias)
All outcomes
High risk Final analysis was done with only the com-
pleters; 4 out of 7 people who were still using
ventilation and all the 6 people in sham group
Selective reporting (reporting bias) Unclear risk All outcomes listed in the Methods were re-
ported
Other bias Low risk The study appears to be free of other source
of bias
McEvoy 2009
Methods Randomised, parallel, controlled study
Participants 144 people with COPD randomised; FEV1 0.59 L, PaCO2 53.5 mmHg. Raw data 81
people with COPD, FEV1 0.65 L, PaCO2 54 mmHg
Interventions 72 people received standard care plus nocturnal-NIPPV (IPAP 13, EPAP 5) for 24
months and 72 continued optimal standard care
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McEvoy 2009 (Continued)
Outcomes After 12 months: BGA, lung function, sleep studies (total sleep time in only NIPPV
group), HRQoL (SGRQ and SF-36), hospitalisation rates (days on trial:days in hospital
rate), survival
Notes Funding: AustralianNationalHealth andMedical ResearchCouncil, Air LiquideHealth-
care, Australian Lung Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned...”
Allocation concealment (selection bias) Low risk Quote: “The central study coordinator gener-
ated a random sequence of treatment assign-
ments that were stratified by centre and dis-
tributed in blocks of 10 sealed opaque en-
velopes to centres”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No blinding for participants, intervention or
personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All primary analyses were conducted
on an intention-to-treat basis. However, since
a proportion of patients assigned toNIV treat-
ment did not use the treatment regularly or
abandoned it altogether after a time, a planned
per protocol sub analysis was conducted com-
paring outcomes of patients in the treatment
arm who used NIV consistently (defined as
average > 4 hours per night) with patients in
the control arm”
Selective reporting (reporting bias) Unclear risk All outcomes listed in the Methods were re-
ported
Other bias Low risk The study appears to be free of other source of
bias
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Meecham Jones 1995
Methods Randomised, controlled, cross-over study
Participants 18 people with COPD randomised, FEV1 0.86 L, PaCO2 56 mmHg. Raw data 14
people with COPD, FEV1 0.84 L, PaCO2 56 mmHg
Interventions Nocturnal-NIPPV (IPAP 18, EPAP 2) for 3 months, while the control group continued
optimal medical care including long-term oxygen
Outcomes After 3 months: BGA, lung function, 6MWD, HRQoL, sleep study (sleep efficiency)
Notes Funding: supported by a grant from the British Lung Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was achieved with
a previously generated randomised se-
quence”
Allocation concealment (selection bias) Low risk Quote from correspondence: “The se-
quence was kept by another research fellow
unconnectedwith the study and Iwasmade
aware of the randomisation as patients were
recruited”




Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Fourteen of the 18 patients com-
pleted all stages of the study.” Reasons
for withdrawal for all 4 participants were
mentioned. One patient did not tolerate
NIPPV. Final analysis was done with the 14
completers
Selective reporting (reporting bias) Unclear risk All outcomes listed in the Methods were
reported
Other bias Low risk The study appears to be free of other source
of bias
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Sin 2007
Methods Randomised, parallel, controlled study
Participants 23 people with COPD randomised; FEV1 0.86 L, PaCO2 44.2 mmHg. Raw data 17
people with COPD, FEV1 0.88 L, PaCO2 43 mmHg
Interventions 11 people received standard medical therapy plus nocturnal-NIPPV (IPAP 16, EPAP 4)
for 3 months while 12 people received standard medical therapy plus sham NIPPV
Outcomes After 3 months: BGA, lung function and 6MWD
Notes Funding: this project is supported by Canadian Institutes of Health Research (clinical
trials), The Institute of Health Economics, and the University of Alberta Hospital Foun-
dation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Recruited patients were randomly as-
signed to...”
Allocation concealment (selection bias) Low risk Quote: “Randomization occurred at a central
site by one individual who was unaware of pa-
tients’ clinical status”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind design. Participants were blind
to intervention treatment (NIPPV versus
sham) and: “All outcome measurements were
performed and interpreted by personnel who
were blinded to treatment allocation of pa-
tients”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Two out of eleven subjects refused
any nocturnal therapy following randomisa-
tion and were excluded from the main analy-
sis”
Selective reporting (reporting bias) Unclear risk All outcomes listed in the Methods were re-
ported
Other bias Unclear risk At baseline no significant differences except
for FEV1, which was significantly higher in
the group that received NIPPV
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Strumpf 1991
Methods Randomised, controlled, cross-over study
Participants 19 people with COPD randomised, FEV1 0.54 L, PaCO2 49 mmHg. Raw data 7 people
with COPD, FEV1 0.54 L, PaCO2 46 mmHg
Interventions Nocturnal-NIPPV (IPAP 15, EPAP 2) for 3 months, while the control group continued
optimal medical care
Outcomes BGA, lung function, PImax/ PEmax, sleep study (sleep efficiency), walking test (treadmill
walking time), dyspnoea (Transitional Dyspnea Index)
Notes Funding: supported in part by a grant fromRespironics, Inc., Monroeville, Pennsylvania
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Using a randomised, crossover de-
sign...”
Allocation concealment (selection bias) Low risk Quote (from correspondence): “Com-
puter-generated random number sequence
placed in envelopes that were opened as pa-
tients were enrolled”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants: no blinding for treatment
(cross-over)
Quote: “All physiological measurements
were performed by personnel blind to treat-
ment and not involved in the study”
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for withdrawal from study were
mentioned for every participant. 7 people
withdrew due to intolerance, 5 of intercur-
rent illness. Final analysis in articlewas done
with the 7 people who completed both arms
Selective reporting (reporting bias) Unclear risk All outcomes listed in the Methods were
reported
Other bias Low risk The study appears to be free of other source
of bias
6MWD: 6-minute walking distance; BGA: blood gas analysis; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory
volume in 1 second; HRQoL: health-related quality of life; MRC: Medical Research Council scale; MRF-28: Maugeri Respiratory
Failure questionnaire-28;NIPPV: non-invasive positive pressure ventilation; PaCO2 : arterial carbon dioxide tension; PImax:maximal
inspiratory pressure; PEmax: maximal expiratory pressure; QoL: quality of life; SF-36: Short Form - 36 items; SGRQ: St. George’s
Respiratory Questionnaire.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Clini 1998 The assignment of the participants to the 2 groups was not randomised
Diaz 1999 Participants received NIPPV for 3 hours a day. We believe that NIPPV should be applied during the night for at
least 5 hours per night
Kamei 1999 The assignment of the participants to either NIPPV or long-term oxygen therapy groups was not randomised
Lin 1996 Participants received NIPPV for only 2 weeks. It is difficult to start NIPPV in people with COPD, therefore, it is
necessary to determine the effects after a longer period so the participants can adjust to the ventilator
Renston 1994 People received NIPPV for 2 hours a day for 5 day. We believe that NIPPV should be applied during the night for
at least 5 hours per night
COPD: chronic obstructive pulmonary disease; NIPPV: non-invasive positive pressure ventilation.
Characteristics of studies awaiting assessment [ordered by study ID]
Xiang 2007
Methods Randomised, parallel controlled study
Participants 40 people with COPD
Interventions Nocturnal-NIPPV and long-term oxygen therapy versus long-term oxygen therapy alone for 2 years
Outcomes BGA, lung function, dyspnoea, 6MWD, respiratory muscle score, mortality, hospital admissions, dropout rate,
anxiety scores
Notes The article was written in Chinese. This study probably meets the review eligibility criteria, but verifying how the
study was conducted based on the English information available was not possible as authors did not respond to clarify
important issues
6MWD: 6-minute walking distance; BGA: blood gas analysis; COPD: chronic obstructive pulmonary disease; NIPPV: non-invasive
positive pressure ventilation.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Results of meta-analysis individual patient data
Outcomes Trial Number (noctur-
nal-NIPPV/
control)
Tx Effect* 95% CI Homogeneity of Tx
Effect, P Value






79/83 1.30 -0.71 to 3.30 0.4787
PaO2 (12 months) Clini 2002;McEvoy
2009
62/56 -1.77 -8.60 to 5.07 0.2412


















21/19 27.7 -11.0 to 66.3 0.5662
6MWD (12
months)





50/53 0.90 -19.21 to 21.01 0.0288





42/41 -0.01 -0.09 to 0.07 0.2413
FEV1 (12 months) Clini 2002;McEvoy
2009
63/62 -0.01 -0.07 to 0.04 0.7445
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Table 1. Results of meta-analysis individual patient data (Continued)






42/40 0.00 -0.13 to 0.14 0.9570
FVC (12 months) Clini 2002;McEvoy
2009
63/62 0.04 -0.12 to 0.20 0.4510
PImax (3 months) Casanova 2000;
Gay 1996; Strumpf
1991
24/24 4.87 -1.48 to 11.21 0.5538
PImax (12
months)
Clini 2002 29/23 -2.31 -9.50, 4.89 -
PEmax (3 months) Casanova 2000;
Gay 1996; Strumpf
1991







13/11 -9.11 -38.09 to 19.86 0.0022
6MWD: 6-minute walking distance; CI: confidence interval; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity;
NIPPV: non-invasive positive pressure ventilation; PaCO2: arterial carbon dioxide tension; PaO2:arterial oxygen tension; PEmax:
maximal expiratory pressure; PImax: maximal inspiratory pressure; SGRQ-Total: total score on the St. George’s Respiratory Ques-
tionnaire; Tx effect: treatment effect.
* An overall treatment effect (mean difference and associated 95% CI) was obtained from the difference in scores under each study
condition (NIPPV minus controls). Individual patient data were analysed using a linear mixed model to compare the treatment effects.
Treatment and time of follow-up (3 and 12 months) were analysed with interaction terms as fixed factors. To consider the homogeneity
among trials, a random factor was defined in the statistical models. Statistical significance (P value < 0.05) in the test of homogeneity
suggested that the observed difference in the treatment effects was in part attributable to the study effect.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search






Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
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MEDLINE search strategy used to identify trials for the CAGR
COPD search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.






Filter to identify RCTs
1. exp “clinical trial [publication type]”/









11. 9 not (9 and 10)
12. 8 not 11
(The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases)
WH A T ’ S N E W
Date Event Description
4 June 2014 Amended PLS title amended
H I S T O R Y
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Date Event Description
1 February 2013 New search has been performed New literature search done
28 January 2013 New citation required but conclusions have not changed A new search was performed which identified 3 new
eligible studies (Clini 2002; McEvoy 2009; Sin 2007).
One trial is listed as ’awaiting classification’ until we can
clarify the methods used in their study. The review has
been re-written and there has been a change to the list
of authors and the review now also contains long-term
data (after 12 months)
13 August 2008 Amended Converted to new review format.
2 January 2002 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Update 2012: Struik and Wijkstra searched and reviewed relevant papers, collected IPD of the newly included RCTs, authors of the
review. Lacasse: statistical analysis of IPD, co-author of the review. Goldstein and Kerstjens: review development, co-author of the
review.
Original review: Wijkstra: searched and reviewed relevant papers, collected IPD of included RCTs, author of the review. Lacasse:
statistical analysis of IPD, co-author of the review. Guyatt: co-author of the review. Goldstein: search and reviewing of relevant papers,
co-author of the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We selected three of the primary outcomes from the last update as our primary outcomes in consultation with the Cochrane Airways
Group.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Diaphragm [physiopathology]; Hypercapnia [etiology; physiopathology; ∗therapy]; Partial Pressure; Positive-Pressure Respiration
[∗methods]; Pulmonary Disease, Chronic Obstructive [complications; physiopathology; ∗therapy]; Pulmonary Gas Exchange; Quality
of Life; Sleep [physiology]; Time Factors; Walking
MeSH check words
Humans
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